Eton Pharmaceuticals Inc(ETON) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Index | RUT | P/E | 45.31 | EPS (ttm) | 1.51 | Insider Own | 4.93% | Shs Outstand | 28.8M | Perf Week | 34.86% |
| Market Cap | 1.97B | Forward P/E | 23.63 | EPS next Y | 44.03% | Insider Trans | -32.5% | Shs Float | 27.4M | Perf Month | 28.26% |
| Enterprise Value | 1.94B | PEG | 0.19 | EPS next Q | 0.53 | Inst Own | 72.62% | Short Float | 7.24% | Perf Quarter | 67.65% |
| Income | 0.05B | P/S | 13.99 | EPS this Y | 474.29% | Inst Trans | 10.41% | Short Ratio | 3.29 | Perf Half Y | 121.93% |
| Sales | 0.14B | P/B | 22.68 | EPS next 5Y | 125.39% | ROA | 38.1% | Short Interest | 1.99M | Perf YTD | 304.49% |
| Book/sh | 3.02 | P/C | 35.46 | EPS past 3/5Y | 21.89% 33.66% | ROE | 90.62% | 52W High | 0.03% ($68.38) | Perf Year | 287.32% |
| Cash/sh | 1.93 | P/FCF | 51.62 | Sales past 3/5Y | 55.53% 359.57% | ROIC | 50.28% | 52W Low | 379.33% ($14.27) | Perf 3Y | 1681.25% |
| Dividend Est. | - | EV/EBITDA | 42.51 | EPS Y/Y TTM | 806.82% | Gross Margin | 69.15% | Volatility(W/M) | 10.63% 6.27% | Perf 5Y | 1304.52% |
| Dividend TTM | - | EV/Sales | 13.76 | Sales Y/Y TTM | 100.61% | Oper. Margin | 28.85% | ATR (14) | 3.97 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.58 | EPS Q/Q | 1580.03% | Profit Margin | 35.35% | RSI (14) | 73.32 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.79 | Sales Q/Q | 157.91% | SMA20 | 28.36% ($53.29) | Beta | 0.8 | Target Price | $80.75 |
| Payout | - | Debt/Eq | 0.28 | Earnings | 2026/11/5 | SMA50 | 23.93% ($55.19) | Rel Volume | 1.88 | Prev Close | $67.54 |
| Employees | 44 | LT Debt/Eq | 0.14 | EPS/Sales Surpr. | 239.2% 37.97% | SMA200 | 82.98% ($37.38) | Avg Volume(3M) | 0.60M | Price | $68.4 |
| IPO | 2018/11/13 | Option/Short | Yes/Yes | Trades | 11167 | Volume | 1,133,881 | Change | 1.27% |
💊 Eton Pharmaceuticals (ETON) is a US-based specialty pharmaceutical company focused on rare diseases. The company concentrates on directly commercializing treatments for ultra-rare diseases with small patient populations in the US, and holds a portfolio of multiple commercial products along with a late-stage development pipeline in the pediatric, metabolic, and endocrine areas.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded more than usual. That is 188% of its average volume.
ETON makes money exceptionally well
Of every $100 in sales, $28.85 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +474.3% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $2,363. Peers typically go for $1,402.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +1304.5%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 72.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
XPH State Street SPDR S&P Pharmaceuticals ETF 0.01% 
PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF 0.01% 
AFSM First Trust Active Factor Small Cap ETF 0.01% 
OMFS Invesco Russell 2000 Dynamic Multifactor ETF <0.01% 
ACSG American Century Small Cap Growth Insights ETF <0.01% It ranks #26 of 83 in the industry
Based on market cap of $2B.
TRLV#24 Trulieve Cannabis Corp $2B PER - 
PBH#25 Prestige Consumer Healthcare Inc $2B PER 13.6 ETON#26 Eton Pharmaceuticals Inc $2B PER 45.3 
BCRX#27 Biocryst Pharmaceuticals Inc $2B PER - 
ALVO#28 Alvotech $2B PER - 
FAQ
What kind of company is ETON?
ETON belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ETON?
The market cap of ETON is approximately $2.0B, ranking 2,065 within its sector.
What is the P/E ratio of ETON?
ETON has a P/E ratio of approximately 45.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ETON?
ETON has recorded a 52-week high of $68.38 and a low of $14.27.
